Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL)

Autor: Kathrin Heinzmann, Gareth J. Veal, Laura Brotherton, William Townsend, Martin J. S. Dyer, Chris M. Bacon, Ilaria Dragoni, Pamela McKay, Elizabeth Ruth Plummer, Hector C. Keun, Harriet S. Walter, Kim Linton, Steve R. Wedge, Sarah Halford, Alexandros P. Siskos

Publikováno v: Halford, S E R, Walter, H, McKay, P, Townsend, W, Linton, K, Heinzmann, K, Dragoni, I, Brotherton, L, Veal, G, Siskos, A, Keun, H C, Bacon, C, Wedge, S, Dyer, M J S & Plummer, E R 2021, ' Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ', Journal of Clinical Oncology, vol. 39, no. 15_suppl, pp. 3115-3115 . https://doi.org/10.1200/jco.2021.39.15_suppl.3115
ASCO Annual Meeting I

3115 Background: Tumours rely on lactate transporters (MCT1-4) to maintain glycolytic flux and avoid intracellular acidification. In haematological tumours the MCT1 transporter acts as a lactate and pyruvate exporter. AZD3965 is a potent and specific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90d8d48f356d0ee9e4a7761b45a9d92
https://doi.org/10.1200/jco.2021.39.15_suppl.3115

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.